Drug Profile
Anatumomab mafenatox
Alternative Names: ABR 214936; PNU 214936; TTS CD2Latest Information Update: 04 Oct 2005
Price :
$50
*
At a glance
- Originator Active Biotech
- Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Pancreatic cancer; Renal cancer
Most Recent Events
- 10 May 2004 Discontinued - Phase-I for Non-small cell lung cancer in Europe (unspecified route)
- 10 May 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (unspecified route)
- 10 May 2004 Discontinued - Phase-II for Pancreatic cancer in United Kingdom (unspecified route)